April 25ctrpc, Hanyu Pharmaceutical expressed at Hutong Yi about the progress of orders for GLP-1 API. Recently, Hanyu Pharmaceutical (Wuhan) Co., Ltd., a wholly-owned subsidiary of the company, signed a "Product Supply Agreement" with DS3RX LLC.
According to the contract, the customer expects the total purchase amount from the Wuhan subsidiary to be approximately US$22.4 million-24 million (equivalent to approximately RMB 1ctrpc.62 billion yuan-1ctrpc.74 billion yuan, ultimately based on the actual transaction).
Hanyu Pharmaceutical said that as of a few days ago, the company had received orders for GLP-1 API from overseas customers in September 2023, equivalent to RMB 219 million, and has been shipping it one after another.ctrpc; In November 2023 and February 2024, orders for the export of liraglutide injectable preparations to the United States were received from the same overseas customer, with a total transaction amount equivalent to RMB 175 million and a profit share of the product was enjoyed. The promotion of international business will help enhance the company's international popularity, enhance market competitiveness, and promote the company's long-term development.